This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-07. Anything still debated is marked as such rather than presented as settled.
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成，纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同，前者常缺少完整药典验证。不同批次间杂质谱是否影响活性，仍是一个需要具体数据回答的问题。
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| Property | Value | Notes |
|---|---|---|
| 外观 | 白色至类白色冻干粉 | 可能具吸湿性 |
| 溶解性 | 溶于水和水性缓冲液 | 典型肽类行为 |
| 冻干粉储存 | -20°C 或 2-8°C，避光 | 长期稳定性较好 |
| 复溶后储存 | 2-8°C，短期 | 避免反复冻融 |
| 常用分析 | RP-HPLC 与 LC-MS | 纯度与身份确认 |
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Regulatory position depends on jurisdiction and on the form in which the material is sold. A branded product holds approval in the United States for a defined indication, and prescribing is confined to that label. Material marketed for laboratory research is not evaluated for human use and carries no such clearance. Independent verification therefore rests on certificates of analysis, third-party testing, and documented chain of custody. The substance also appears on the World Anti-Doping Agency prohibited list within the category covering growth hormone-releasing factors.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
==== In males ==== It is secreted from the Sertoli cells, located in the seminiferous tubules inside the testes. Androgens stimulate inhibin production; this protein may also help to locally regulate spermatogenesis.
Angiotensinogen is an α-2-globulin synthesized in the liver and is a precursor for angiotensin, but has also been indicated as having many other roles not related to angiotensin peptides. It is a member of the serpin family of proteins, leading to another name: Serpin A8, although it is not known to inhibit other enzymes like most serpins. In addition, a generalized crystal structure can be estimated by examining other proteins of the serpin family, but angiotensinogen has an elongated N-terminus compared to other serpin family proteins. Obtaining actual crystals for X-ray diffractometric analysis is difficult in part due to the variability of glycosylation that angiotensinogen exhibits. The non-glycosylated and fully glycosylated states of angiotensinogen also vary in molecular weight, the former weighing 53 kDa and the latter weighing 75 kDa, with a plethora of partially glycosylated states weighing in between these two values. Angiotensinogen is also known as renin substrate. It is cleaved at the N-terminus by renin to result in angiotensin I, which will later be modified to become angiotensin II. This peptide is 485 amino acids long, and 10 N-terminus amino acids are cleaved when renin acts on it. The first 12 amino acids are the most important for activity.
{\displaystyle \int \limits _{\Omega }\rho {\frac {\partial \mathbf {u} }{\partial t}}\cdot \mathbf {v} -\int \limits _{\Omega }\mu \Delta \mathbf {u} \cdot \mathbf {v} +\int \limits _{\Omega }\rho (\mathbf {u} \cdot \nabla )\mathbf {u} \cdot \mathbf {v} +\int \limits _{\Omega }\nabla p\cdot \mathbf {v} =\int \limits _{\Omega }\mathbf {f} \cdot \mathbf {v} }
Sources: en.wikipedia.org
Jurewizc further argues that the rest of the twelve nidanas show similarities with the terms and ideas found in Vedic cosmogeny, especially as it relates to the sacrificial fire (as a metaphor for desire and existence). These Vedic terms may have been adopted by the Buddha to communicate his message of not-self because his audience (often educated in Vedic thought) would understand their basic meaning. According to Jurewizc, dependent origination replicates the general Vedic creation model, but negates its metaphysics and its morals. Furthermore, Jurewizc argues that:This deprives the Vedic cosmogony of its positive meaning as the successful activity of the Absolute and presents it as a chain of absurd, meaningless changes which could only result in the repeated death of anyone who would reproduce this cosmogonic process in ritual activity and everyday life.According to Gombrich, the Buddhist tradition soon lost sight of their connection with the Vedic worldview that the Buddha was critiquing in the first four links of dependent origination. Though it was aware that at the fourth link there should be an appearance of an individual person, the Buddhist tradition equated rupa with the first skandha, and nama with the other four skandhas. Yet, as Gombrich notes, samkhara, vijnana, and vedana also appear as separate links in the twelvefold list, so this equation can't be correct for this nidana.
The term "Han" not only refers to a specific ethnic collective, but also points to a shared ancestry, history, and cultural identity. The term "Huaxia" was used by the ancient Chinese philosopher Confucius's contemporaries during the Warring States period to elucidate the shared ethnicity of all Chinese; Chinese people called themselves "Hua people" (华人; 華人; Huárén). The Warring States period led to the emergence of the Zhou-era Chinese referring to themselves as being Huaxia (literally 'the beautiful grandeur'): under the Hua–Yi distinction, a "Hua" culture (often translated as 'civilized') was contrasted to that of peoples perceived as "Yi" (often translated as 'barbarian') living on the peripheries of the Zhou kingdoms. Overseas Chinese who possess non-Chinese citizenship are commonly referred as Huaren or Huazu (华族; 華族; Huázú). The two respective aforementioned terms are applied solely to those with a Han background that is semantically distinct from Zhongguo ren (中国人; 中國人) which has connotations and implications limited to being citizens and nationals of China, especially with regard to ethnic minorities in China. In English, the terms "Han Chinese", "ethnic Chinese", and "Chinese" people, are often conflated.
=== Broadway === Todd acted on and off Broadway. Among his many roles are August Wilson's King Hedley II, Athol Fugard's The Captain's Tiger, for which he received the Helen Hayes nomination. Others include No Place to be Somebody, Les Blancs, Playboys of the West Indies, Othello, Zooman and The Sign, award-winning playwright Keith Glover's Dark Paradise, Aida (on Broadway), and Levee James for the Eugene O'Neill Playwrights Conference and The New Dramatist Guild.
== Safety == No major serious adverse events have been reported; however, long-term cardiovascular safety has not been established. Concerns have been raised regarding increase in serum creatinine with the use of saroglitazar, initially noted in a meta-analysis published by Dutta et al. In another randomized controlled trial published by Gawrieh et al., a mild but significant increase in serum creatinine was noted with 16 weeks use of saroglitazar at 4mg/day dose.
Sources: en.wikipedia.org
== Electronic Associates, Inc. == In 1963, Finnigan and Uthe joined Electronic Associates, Inc. (EAI). The main research department of the company was based in Princeton, New Jersey, but Finnigan founded a new Scientific Instruments Division in Palo Alto, California. Finnigan's vision involved creation of a broad-based line of process-control instruments, beginning with the quadrupole mass spectrometer. Based on previous research at SRI, Finnigan was convinced that a market existed, but EAI and other companies such as IBM and Beckman Instruments were not interested in developing the quadrupole as a product at that time. Finnigan's group proposed to contract parts of the quadrupole production to SRI, but management at SRI were not interested in its commercial development either. Eventually Finnigan collaborated with staff from SRI, who supplied knowledge and expertise to help Finnigan's group bootstrap development of a prototype quadrupole analyzer at EAI. Because of the strong market demand the EAI division was able to sell more than 500 of these quadrupole residual gas analyzers between 1964 and 1966. Finnigan wanted to pursue development of computer-controlled instrumentation for a combined gas chromatograph (GC) and quadrupole mass spectrometer (MS). However, EAI's main focus was analog computers, and they were not interested in developing a computerized GC/MS. On December 31, 1966, after EAI unsuccessfully attempted to sell the division to Syntex Corporation, Finnigan submitted his resignation to EAI.
In addition to its role as a natural hormone, estradiol is used as a medication, for instance in menopausal hormone therapy, and feminizing hormone therapy for transgender women and some genderqueer individuals; for information on estradiol as a medication, see the estradiol (medication) article.
=== Personal life === Flory was born in Sterling, Illinois, on June 19, 1910 to Ezra Flory and Martha Brumbaugh. His father worked as a clergyman-educator, and his mother was a school teacher. His ancestors were German Huguenots, who traced their roots back to Alsace. He first gained an interest in science from Carl W Holl, who was a chemistry professor at Manchester College. In 1936, he married Emily Catherine Tabor. They had three children together: Susan Springer, Melinda Groom and Paul John Flory, Jr. His first position was at DuPont with Wallace Carothers. He was posthumously inducted into the Alpha Chi Sigma Hall of Fame in 2002. Flory died on September 9, 1985, following a heart attack. His wife Emily died in 2006 aged 94.
=== Selective ion monitoring === In selective ion monitoring (SIM) certain ion fragments are entered into the instrument method and only those mass fragments are detected by the mass spectrometer. The advantages of SIM are that the detection limit is lower since the instrument is only looking at a small number of fragments (e.g. three fragments) during each scan. More scans can take place each second. Since only a few mass fragments of interest are being monitored, matrix interferences are typically lower. To additionally confirm the likelihood of a potentially positive result, it is relatively important to be sure that the ion ratios of the various mass fragments are comparable to a known reference standard.
As such, EMP therapy results in considerably stronger androgen deprivation than orchiectomy. Metabolites of EMP, including estramustine, estromustine, estradiol, and estrone, have been found to act as weak antagonists of the androgen receptor (EC50Tooltip half-maximal effective concentration = 0.5–3.1 μM), although the clinical significance of this is unknown. Extremely high levels of estradiol and estrone occur during EMP therapy. The estrogenic metabolites of EMP are responsible for its most common adverse effects and its cardiovascular toxicity. EMP has been described as having relatively weak estrogenic effects in some publications. However, it has shown essentially the same rates and degrees of estrogenic effects, such as breast tenderness, gynecomastia, cardiovascular toxicity, changes in liver protein synthesis, and testosterone suppression, as high-dose diethylstilbestrol and ethinylestradiol in clinical studies. The notion that EMP has relatively weak estrogen activity may have been based on animal research, which found that EMP had 100-fold lower uterotrophic effects than estradiol in rats, and may also not have taken into account the very high doses of EMP used clinically in humans. The mechanism of action of the cytostatic effects of EMP is complex and only partially understood. EMP is considered to mainly be a mitotic inhibitor, inhibiting mechanisms involved in the mitosis phase of the cell cycle.
Sources: en.wikipedia.org
反相高效液相色谱用于分离和纯度评估，质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。
高温、强光、潮湿和反复冻融都会加速肽降解。冻干粉通常建议低温避光保存。复溶后的溶液稳定性较短，应依据验证数据确定保存条件。
氧化、脱酰胺和截短肽可能影响色谱纯度和生物活性读数。不同批次之间这些杂质的相对比例可能不同。是否具有临床意义取决于杂质水平、给药途径和暴露量，尚无统一阈值。
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.